Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
Arthritis Research & Therapy, 09/05/08
Rosengren S et al. – Combined with earlier observations that synovial lymphoid aggregates survived rituximab treatment, these data suggest that lymphoid aggregates may provide a protective niche for autoantibody producing cells.
Methods- Study to evaluate the contribution of synovial lymphoid aggregates to autoantibody, total immunoglobulin production in RA pts, and the effect of the B-cell depleting ab, rituximab
- Autoantibodies, total IgM and IgG were quantified by ELISA in extracts of synovial tissues and matched serum
- Synovial biopsies and serum were obtained at baseline and 8 wks following rituximab therapy in 14 RA pts
- Anti-CCP IgG, but not RF-IgM, was enriched in RA synovia vs serum
- Total IgM and IgG was also enriched in RA, but not in OA
- SSI correlated with mRNA content for both IgM and IgG
- RA synovia with lymphocyte aggregates contained elevated RF-IgM and anti-CCP IgG vs tissues with diffuse lymphoid infiltration
- Rituximab treatment did not affect synovial autoantibody or total Ig SSI overall
- In aggregate-containing tissues, rituximab reduced total IgM and IgG SSI as well as IgM and IgG1 mRNA
- RF-IgM and anti-CCP IgG synovial/serum indices were unchanged by rituximab in aggregate-containing synovial
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study
Arthritis Research & Therapy, 10/16/09
The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
Arthritis & Rheumatism, 11/04/09
Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research , 11/02/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09
Sponsor
Article Search
Sponsor


See Latest Articles


